Millions of people are affected by clotting and bleeding disorders. Thrombotic-related events are a leading cause of death worldwide, which is why it is an important time for researchers and clinicians in this field.
Dr. Jerrold Levy, Co-Director of the Cardiothoracic ICU and a professor of anesthesiology, is the first author of an article published in the December 2015 issue of the Journal of Thrombosis and Haemostasis (JTH), the official journal of the International Society on Thrombosis and Haemostasis (ISTH). “When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH” talks about the direct oral anticoagulants (DOACs) and explains why antidotes would be useful as one component of strategies for management of serious bleeding, or for rapid reversal of the DOACs prior to urgent interventions. The direct oral anticoagulants (DOACs) are licensed for stroke prevention in patients with atrial fibrillation and for prevention and treatment of venous thromboembolism. The article describes the mechanism of action of the antidotes for the DOACs, reviews the available clinical data, and provides guidance on potential indications for their use.
ISTH is the major coagulation society of the world. As a global membership community of specialists in bleeding and clotting disorders, ISTH is dedicated to transformative scientific discoveries to advance clinical practice and improve the lives of millions of people worldwide. Many recent discoveries in thrombosis and hemostasis have been the result of research conducted by ISTH members.
A permanent committee of the ISTH, the Scientific and Standardization Committee (SSC), create projects that respond to a variety of challenges in the fields of thrombosis and haemostasis. The SSC has 20 subcommittees, including the “Control of Anticoagulation,” which is focused on laboratory and clinical issues related to the use of anticoagulant drugs. Dr. Levy collaborated with other fellow members of this subcommittee for this article.